Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status Prescription; Discontinued
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343; 0703-4685; 0703-4686; 0703-4680
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisTranscription factor JunP05412T690858219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
ApoptosisG1/S-specific cyclin-D1P24385T123558219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Toxicity to various agentsEpoxide hydrolase 1P07099Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Enteritis07.08.03.002--
Erythema23.03.06.001--Not Available
Extravasation08.01.03.008--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.001066%
Feeling abnormal08.01.09.014--Not Available
Foot and mouth disease23.09.03.007; 11.05.04.020; 07.05.07.010--Not Available
Fungal infection11.03.05.001--Not Available
Fungal skin infection23.09.02.001; 11.03.05.002--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Granulocytes abnormal13.01.06.034--Not Available
Granulocytopenia01.02.03.003--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000278%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hyperphosphataemia14.04.03.007--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages